SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X ETF

Direxion Daily S&P Biotech Bull 3X Shares

A rebound in biotech stocks is driving LABU higher, with traders tracking the sectors move through XBI and positioning around upcoming inflation data that could affect rate-sensitive biotech shares. The community is split between expecting the bounce to continue and cautioning that LABUs 3x leverage can magnify pullbacks.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class B

Berkshires quarterly results and stepped-up share repurchases are driving discussion: some traders view the buybacks as a vote of confidence from Greg Abel, while others focus on weaker insurance performance and question whether repurchases can continue.

Stellar (XLM) is a cryptocurrency launched in 2014. Stellar has a current supply of 50,001,786,837.39707 with 35,366,684,616.305855 in circulation. The last known price of Stellar is 0.15346137 USD and is down -1.11 over the last 24 hours. It is currently trading on 848 active market(s) with $109,670,947.94 traded over the last 24 hours. More information can be found at https://www.stellar.org.

Stellar Lumens

XLMs persistent selloff and underperformance dominate discussion, with traders warning of further losses while others treat the decline as a buying opportunity. Bulls point to Stellars tokenization and institutional-adoption prospects, including DTCC-related plans, but skeptics argue that partnerships have not translated into token demand and question the tokenomics.

Accenture is a global professional services company that helps the world’s businesses, governments and other organizations build their digital core, optimize their operations, accelerate revenue growth and enhance citizen services, creating tangible value at speed and scale. The firm combines technology and leadership in cloud, data and AI with industry experience, functional expertise and global delivery capability. Its services include Strategy & Consulting, Technology, Operations, Industry X, and Song. It operates through the following geographical segments: North America, EMEA, and Growth Markets. The company was founded in 1989 and is headquartered in Dublin, Ireland.

Accenture plc - Ordinary Shares - Class A

Accenture is drawing attention as traders question whether enterprise AI projects will translate into sustained consulting revenue or instead reduce billable work and pressure margins. The debate is playing out against a sharp rally and technical resistance, with bearish traders watching for a pullback and bulls pointing to insider buying and continued demand for AI implementation.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

Attention centers on long-term lorundrostat data reporting that blood-pressure benefits persisted for two years after treatment ended, alongside the upcoming FDA decision on the hypertension drug. Traders view the durability findings as encouraging but remain divided amid the stocks weakness and the binary regulatory catalyst.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Foxs acquisition of Roku has closed, ending ROKUs run as a standalone Nasdaq-listed company and shifting holders into the deals cash-and-Fox-stock consideration. The community is marking the end of the ticker with a mix of congratulations and disappointment that the sale capped Rokus potential, while some traders are also discussing bullish call activity.

J.P. Morgan Exchange-Traded Fund Trust - JPMorgan Nasdaq Equity Premium Income ETF

JPMorgan Nasdaq Equity Premium Income ETF

A Nasdaq and technology-sector selloff is weighing on JEPQ, prompting traders to compare its decline with the broader tech pullback. Many are buying the dip for monthly income, while others question whether distributions offset the funds price weakness and limited upside from its covered-call strategy.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus is drawing attention for the potential of its ITK inhibitor soquelitinib across several clinical indications, with traders watching for trial updates and possible partnerships. Optimists point to the science and reported institutional or insider buying, while skeptics focus on delayed data, the long path to revenue, and persistent short interest.

Invesco DB US Dollar Index Bullish Fund - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

A rebound in the U.S. dollar, with traders watching payrolls data and the Fed rate outlook, is the main focus for UUP. Some see continued dollar strength as a headwind for stocks and precious metals, while others question whether the move will last.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroups latest quarterly results beat expectations, but shares have fallen as traders question the reaction and focus on higher credit-loss provisions, weaker card profitability, and continued investment spending. Some view the selloff as a disconnect from improving earnings, while others are concerned about credit quality and broader weakness in bank stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

All You Need to Know About OrthoPediatrics (KIDS) Rating Upgrade to Buy

OrthoPediatrics (KIDS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Notable Wednesday Option Activity: KIDS, TOST, GLXY

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in OrthoPediatrics Corp (Symbol: KIDS), where a total volume of 1,750 contracts has been traded thus far today, a contract volume which is representative of approxi...

OrthoPediatrics: 3 Key Takeaways for Long-Term Investors

Key PointsOrthoPediatrics raised 2026 revenue guidance to $270 million to $273 million...

OrthoPediatrics (KIDS) Q3 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

OrthoPediatrics Q3 2026 Earnings Call Transcript

OrthoPediatrics (NASDAQ:KIDS) reported third-quarter financial results on Tuesday. The transcript from the company's third-quarter earnings call has been provided below.This transcript is brought to you by Benzingaread more...

OrthoPediatrics (KIDS) Reports Q3 Loss, Tops Revenue Estimates

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of +8.00% and +6.01%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

OrthoPediatrics (KIDS) Q2 2026 Earnings Call Transcript

OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates

OrthoPediatrics (KIDS) delivered earnings and revenue surprises of +16.13% and +3.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Is the Selloff in OrthoPediatrics Corp. (KIDS) Creating a Buying Opportunity?

Is the Selloff in OrthoPediatrics Corp. (KIDS) Creating a Buying Opportunity...

OrthoPediatrics (NASDAQ:KIDS) Given "Buy" Rating at BTIG Research

BTIG Research restated a "buy" rating and issued a $24.00 target price on shares of OrthoPediatrics in a research note on Friday...

• Reported GAAP EPS of -$0.23 up 4.17% YoY
• Reported revenue of $72.66M up 18.63% YoY
• OrthoPediatrics increased full year 2026 revenue guidance to $270M to $273M from $265M to $269M, representing growth of 14% to 16% over 2025 revenue.

OrthoPediatrics recorded a net loss, reported operating expenses of $58.2M, up 6%, and disclosed widespread health-emergency risks that may affect product demand and its ability to respond to related challenges.

OrthoPediatrics reported record revenue and growth in Trauma and Deformity and Scoliosis, expanded its pediatric product portfolio through new launches, and posted higher adjusted EBITDA with positive third-quarter free cash flow.

OrthoPediatrics Corp. is an orthopedic company, which engages in the design, development, and marketing of anatomically appropriate implants and devices for children with orthopedic conditions. It offers products relating to trauma and deformity, scoliosis, and sports medicine and other procedures. The company was founded by Erin Springer Yount and Nick A. Deeter on August 31, 2006 and is headquartered in Warsaw, IN.

OrthoPediatrics corp

Bearish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

KIDS News